The Canadian R&D company Entheon Biomedical has set out to investigate the therapeutic use of the psychedelic dimethyltryptamine (DMT) in treating addiction disorders. Specifically, the company has commissioned a clinical trial investigating the safety and efficacy of using intravenous DMT.
Whether you’ve traded for decades or just opened an account, the market attracts you for a reason.
Phoenix, Arizona--(Newsfile Corp. - January 20, 2021) - The Stock Day Podcast welcomed Silo Pharma Inc. (OTCQB: SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson's, and other rare neurological disorders. CEO of the Company, Eric Weisblum, joined Stock Day host Everett Jolly.
Cybin's bought deal financing has been upsized to CAD$30 million.
Entheon announces a new partnership to advance its psychedelic drug R&D.
Cybin Corp announces a CAD$20 million financing at a unit price of CAD$2.25.
New research suggests that the public’s perception of the potential harms of magic mushrooms is not in line with drug laws.
Even before Oregon and Washington, D.C., decriminalized medical psilocybin, the active ingredient in “magic mushrooms,” in November, a market was emerging for schools that teach mental and medical health professionals how to use psychedelics in their treatment.
In 2020, psychedelics took the world by storm. Over two dozen companies in the sector became publicly listed.
Local Massachusetts lawmakers on Thursday unanimously approved a resolution to decriminalize a wide range of psychedelics—the latest in a national movement to reform laws on entheogenic plants and fungi.
LONDON — ATAI Life Science, a Peter Thiel-backed start-up, has taken a majority stake in Recognify, a company that is developing drugs to help treat schizophrenia.
The UFC is looking to get involved with research into psychedelic drugs as a therapy for fighters' brain health.
